Vivos Therapeutics, Inc.
VVOS
$0.80
$0.022.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.44M | 17.32M | 14.39M | 14.63M | 15.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.44M | 17.32M | 14.39M | 14.63M | 15.03M |
| Cost of Revenue | 6.90M | 7.66M | 6.34M | 6.04M | 6.01M |
| Gross Profit | 10.54M | 9.65M | 8.05M | 8.59M | 9.02M |
| SG&A Expenses | 29.13M | 24.97M | 21.51M | 19.28M | 19.61M |
| Depreciation & Amortization | 1.31M | 1.01M | 773.00K | 612.00K | 581.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.34M | 33.64M | 28.63M | 25.93M | 26.20M |
| Operating Income | -19.90M | -16.32M | -14.23M | -11.31M | -11.17M |
| Income Before Tax | -21.23M | -17.10M | -14.32M | -11.24M | -11.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.23 | -17.10 | -14.32 | -11.24 | -11.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 60.00K | -- | -- | -- | -- |
| Net Income | -21.17M | -17.10M | -14.32M | -11.24M | -11.14M |
| EBIT | -19.90M | -16.32M | -14.23M | -11.31M | -11.17M |
| EBITDA | -18.59M | -15.31M | -13.46M | -10.69M | -10.59M |
| EPS Basic | -2.05 | -1.88 | -1.79 | -1.83 | -3.01 |
| Normalized Basic EPS | -1.28 | -1.18 | -1.12 | -1.15 | -1.88 |
| EPS Diluted | -2.05 | -1.88 | -1.79 | -1.83 | -3.01 |
| Normalized Diluted EPS | -1.28 | -1.18 | -1.12 | -1.15 | -1.88 |
| Average Basic Shares Outstanding | 41.07M | 35.88M | 31.53M | 25.67M | 19.38M |
| Average Diluted Shares Outstanding | 41.07M | 35.88M | 31.53M | 25.67M | 19.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |